TY - JOUR T1 - Intense expression of Neurokinin-1 Receptor is associated with Urothelial carcinoma JF - bioRxiv DO - 10.1101/2020.06.27.175026 SP - 2020.06.27.175026 AU - Riffat Mehboob AU - Amber Hassan AU - Shahida Perveen AU - Syed Amir Gilani AU - Humera Waseem AU - Fridoon Jawad Ahmad AU - Javed Akram Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/06/28/2020.06.27.175026.abstract N2 - I+ntroduction Substance P (SP)/ Neurokinin-1 Receptor (NK-1R), induces inflammatory reactions in peripheral tissues but its regulatory effects in target tissues are dependent on receptor signaling. SP has a high affinity for the NK-1 receptor, to which it binds preferentially. SP/NK-1R complex plays a key role in the interaction in the onset of pain and inflammation.Objective The aim of this study was to investigate the expression of NK-1R in Urotheilial carcinoma and its association with cancer progression.Method The study included ten biopsy samples of Urinary bladder, obtained retrospectively from a tertiary care hospital of Lahore. An Immunohistochemical study was performed using monoclonal antibodies against NK-1R. The presence or absence of staining and the intensity of the immunoreactivity were noted, as well as the number and type of cells. Evaluation of the Immunohistochemical expression was determined by the semi-quantitative method and scored.Result NK-1 receptor was intensely expressed in patients with higher grade Urotheilial carcinoma. The cases clinically diagnosed as High Grade Urotheilial Carcinoma showed intense expression of NK-1R. However, the cases clinically diagnosed as low grade Urotheilial carcinoma showed very weak staining with NK-1R. However, the normal margins of the same tissue showed negative expression.Conclusions Elevated expression of NK-1R was associated with advanced stage of urothelial carcinoma. It is the first study to our knowledge to report this association. It may serve as a good diagnostic as well as prognostic marker and therapeutic strategy.Competing Interest StatementThe authors have declared no competing interest. ER -